Please check your internet connection and try again.
## Clobazam (Onfi, Sympaza) Oral Formulation
### Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure disorders.
### Primary Indications
Adjunctive therapy for seizures in patients with Lennox-Gastaut syndrome (LGS).
### Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5-10 mg every week based on clinical response and tolerability.
* **Maintenance:** Typically 10-20 mg twice daily, but may be increased up to 40 mg twice daily.
* **Maximum:** 40 mg twice daily (80 mg per day).
### Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS) - Age 2 years and older:**
* **Initiation:** 5 mg once daily.
* **Titration:** Increase dose by 2.5-5 mg every week based on clinical response and tolerability.
* **Maintenance:** Typically 5-10 mg twice daily, but may be increased up to 20 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg per day) for patients weighing less than 30 kg. For patients weighing 30 kg or more, the maximum is 40 mg twice daily (80 mg per day).
* **Note:** Dosing for children under 2 years of age has not been established. Specific dosing protocols may vary; consult local guidelines or specialized epilepsy resources.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Consider a lower starting dose and slower titration.
* **Concomitant Medications:** Dose adjustments may be necessary for significant drug interactions, particularly with CYP3A4 inhibitors/inducers and other CNS depressants.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Severe sleep apnea.
### Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, lethargy, ataxia, gait disturbance, vomiting, diarrhea, drooling, insomnia, upper respiratory tract infection.
* **Serious:** Suicidal ideation and behavior, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, cognitive impairment, paradoxical reactions (e.g., excitation), hyponatremia.
### Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other benzodiazepines, sedatives):** Additive CNS depression, increased risk of respiratory depression, profound sedation, coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease clobazam concentrations.
* **Valproic Acid:** Increased valproic acid concentrations may occur, potentially increasing the risk of valproate-associated toxicity.
* **Perampanel:** Increased risk of CNS adverse effects.
### Monitoring
* Monitor for signs of suicidal ideation and behavior.
* Monitor for excessive sedation and respiratory depression, especially when used with other CNS depressants.
* Assess for signs of dependence and withdrawal symptoms upon discontinuation.
* Monitor for efficacy and adverse effects, particularly at the start of therapy and after dose changes.
* Consider monitoring valproic acid levels if used concomitantly.
### Clinical Pearls
* Clobazam has a longer half-life than many other benzodiazepines, which may allow for less frequent dosing but also increases the risk of accumulation.
* Withdrawal symptoms can occur with abrupt discontinuation. Taper the dose slowly when discontinuing.
* The active metabolite, N-desmethylclobazam, contributes significantly to the pharmacological effect.
* Use with extreme caution in elderly patients due to increased risk of sedation and falls.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always verify current prescribing information and consult with a qualified healthcare provider before making any treatment decisions.*
